VistaGen Fast-Tracked by FDA for SAD Treatment

VistaGen Fast-Tracked by FDA for SAD Treatment

By: Dylan Sikes – AllPennyStocks.com News

Tuesday, December 10, 2019

It’s significant news, given the increased emphasis on better mental health.

San Francisco-based VistaGen Therapeutics, Inc. (NASDAQ:VTGN), announced Tuesday that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for development of the Company's PH94B neuroactive nasal spray for on-demand treatment of social anxiety disorder (SAD).

VistaGen boasts a status as a clinical-stage biopharmaceutical company developing new generation medicines for central nervous system diseases and disorders with high unmet need. 

CEO Shawn Singh exulted, “With a high global prevalence of anxiety disorders, including SAD, and alarming increases in dependency, addiction and even deaths associated with misuse of benzodiazepines, the urgency for a new non-addictive, non-sedating, fast-acting, as-needed treatment for SAD and other anxiety disorders is more important now than ever before.” 

VTGN shares vaulted 23.2 cents, or 54.1%, to 66 cents, on volume of 6.1 million. 

 


Copyright © 2019 AllPennyStocks.com. All rights reserved. Republication or redistribution of AllPennyStocks.com's content is expressly prohibited without the prior written consent of AllPennyStocks.com. AllPennyStocks.com shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon

Other Penny Stock Movers

Canadian Inflation Moves Up as Expected But Easing Underlying Pressures Boost Hopes of June Rate Cut
Shares Up as Firm Launches First Short Spot Bitcoin ETP in the Nordics
Could This Stock Be The Next Big Mover In The Short-Term Rental Market?
Most Popular
FREE Newsletter
AllPennyStocks.com Favorites


Back to Top